Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvimopan for opioid-induced bowel dysfunction in cancer pain subjects
2005-001974-28Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alvimopan in opioid-induced bowel dysfunction (OIBD) (5 arms), sponsored by GSK. Primary endpoint: Change in weekly spontaneous complete bowel movement (SCBM) frequency. Started Aug 2005; status: completed.
02
Drugs
alvimopan
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on 2005-001974-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001974-28.